Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer

Lung Cancer

Volumn 94, Issue , 2016, Pages 108-113

  Dickhoff, C ^a   Dahele, M ^a   Paul, M A ^a   van de Ven, P M ^a   de Langen, A J ^a   Senan, S ^a   Smit, E F ^b   Hartemink, K J ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Chemoradiotherapy; Locoregional recurrence; Non small cell lung cancer; Salvage surgery; Survival

Indexed keywords

ERLOTINIB;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG OVERDOSE; EMPYEMA; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LOCOREGIONAL RECURRENCE; LUNG RESECTION; MALE; MORBIDITY; MORTALITY; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERSISTENT TUMOR; PRIORITY JOURNAL; RADIATION DOSE; SALVAGE THERAPY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84960405720     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.02.005     Document Type: Article

References (12)

1. Eberhardt W.E., De Ruysscher D., Weder W., Le Péchoux C., De Leyn P., Hoffmann H., et al. Panel members. 2nd ESMO consensus conference in lung cancer: locally-advanced stage III non-small-cell lung cancer. Ann. Oncol. 2015, 26:1573-1588.
2. Kozower B.D., Larner J.M., Detterbeck F.C., Jones D.R. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143:e369S-e399S.
3. O'Rourke N., Roqué I., Figuls M., Farré Bernadó N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst. Rev. 2010, 16:CD002140.
4. Bradley J.D., Paulus R., Komaki R., Masters G., Blumenschein G., Schild S., et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015, 16:187-199.
5. Bauman J.E., Mulligan M.S., Martins R.G., Kurland B.F., Eaton K.D., Wood D.E. Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann. Thorac. Surg. 2008, 86:1632-1638.
6. Yang C.F., Meyerhoff R.R., Stephens S.J., Singhapricha T., Toomey C.B., Anderson K.L., et al. Long-Term outcomes of lobectomy for non-Small cell lung cancer after definitive radiation treatment. Ann. Thorac. Surg. 2015, 99:1914-1920.
7. Uramoto H., Tanaka F. Salvage thoracic surgery in patients with primary lung cancer. Lung Cancer 2014, 84:151-155.
8. Kuzmik G.A., Detterbeck F.C., Decker R.H., Boffa D.J., Wang Z., Oliva I.B., et al. Pulmonary resections following prior definitive chemoradiation therapy are associated with acceptable survival. Eur. J. Cardiothorac. Surg. 2013, 44:e66-70.
9. Schreiner W., Dudek W., Sirbu H. Is salvage surgery for recurrent non-small-cell lung cancer after definitive non-operative therapy associated with reasonable survival. Interact. Cardiovasc. Thorac. Surg. 2015, 21:682-684.
10. Tetar S., Dahele M., Griffioen G., Slotman B., Senan S. High-dose conventional thoracic re-irradiation for lung cancer: updated results. Lung Cancer 2015, 88:235-236.
11. McAvoy S., Ciura K., Wei C., Rineer J., Liao Z., Chang J.Y., et al. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int. J. Radiat. Oncol. Biol. Phys. 2014, 90:819-827.
12. Paramanathan A., Solomon B., Collins M., Franco M., Kofoed S., Francis H., et al. Patients treated with platinum-doublet chemotherapy for advanced non-small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation. Clin. Lung Cancer 2013, 14:508-512.